Carcinoembryonic Antigen (CEA)
Use
This assay is intended for the in vitro quantitative determination of carcinoembryonic antigen in human serum and plasma.1 The Elecsys CEA assay is further indicated for serial measurement of CEA to aid in the management of cancer patients. The main indication for CEA determinations is the follow-up and therapy-management of colorectal carcinoma.
Special Instructions
Not provided.
Limitations
CEA determinations are not recommended for cancer screening in the general population. Serum CEA values can vary based on the test procedure and may result in erroneous medical interpretations if different methods are used for comparisons. Erroneous findings may occur in the presence of high titers of antibody to streptavidin and ruthenium. Results should always be considered alongside patient history and other clinical findings.
Methodology
Immunoassay (ECLIA)
Biomarkers
Carcinoembryonic Antigen
Protein
LOINC Codes
- 2039-6 - CEA SerPl-mCnc
- 2039-6 - CEA SerPl-mCnc
Result Turnaround Time
1 day
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.7 mL
Container
Gel-barrier tube (preferred) or red-top tube
Collection Instructions
If a red-top tube is used, transfer separated serum to a plastic transport tube.
Storage Instructions
Room temperature
Causes for Rejection
Citrate plasma specimen; improper labeling
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 7 days |
| Refrigerated | 14 days |
| Frozen | 14 days |
Other tests from different labs that may be relevant